Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2029-05-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pembrolizumab after standard treatment with radiation
plus the following chemotherapy drugs: cisplatin or carboplatin, plus etoposide works in
treating patients with limited stage small cell lung cancer (LS-SCLC). Immunotherapy with
monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Giving
pembrolizumab after standard treatment with radiation plus chemotherapy may increase the
ability of the immune system to fight LS-SCLC.